FRA
NVO

Front Row Advisors’s Novo Nordisk NVO Stock Holding History

Front Row Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-231
Closed -$33K – 737
2024
Q2 		$33K Buy
231
+2
+0.9% +$265 0.01% 321
2024
Q1 		$29.4K Buy
+229
New +$27.3K 0.01% 328
2023
Q4 		– Sell
-241
Closed -$21.9K – 704
2023
Q3 		$21.9K Buy
241
+89
+59% +$7.84K 0.01% 362
2023
Q2 		$12K Sell
152
-16
-10% -$1.31K 0.01% 483
2023
Q1 		$13K Sell
168
-4
-2% -$284 0.01% 467
2022
Q4 		$12K Sell
172
-78
-31% -$4.57K 0.01% 462
2022
Q3 		$13K Sell
250
-48
-16% -$2.57K 0.01% 455
2022
Q2 		$17K Sell
298
-4
-1% -$222 0.01% 427
2022
Q1 		$17K Sell
302
-80
-21% -$4.11K 0.01% 451
2021
Q4 		$21K Sell
382
-2
-0.5% -$108 0.01% 417
2021
Q3 		$18K Sell
384
-4
-1% -$193 0.01% 447
2021
Q2 		$20K Buy
388
+18
+5% +$698 0.01% 422
2021
Q1 		$13K Buy
370
+8
+2% +$285 0.01% 496
2020
Q4 		$13K Sell
362
-16
-4% -$553 0.01% 464
2020
Q3 		$13K Buy
+378
New +$12.6K 0.01% 456
2020
Q1 		– Sell
-88
Closed -$3K – 1020
2019
Q4 		$3K Hold
88
– – ﹤0.01% 730
2019
Q3 		$2K Sell
88
-88
-50% -$2.23K ﹤0.01% 794
2019
Q2 		$4K Hold
176
– – ﹤0.01% 660
2019
Q1 		$5K Sell
176
-192
-52% -$4.72K ﹤0.01% 594
2018
Q4 		$8K Sell
368
-44
-11% -$978 0.01% 441
2018
Q3 		$9 Sell
412
-194
-32% -$4.73K 0.01% 443
2018
Q2 		$15 Buy
606
+192
+46% +$4.56K 0.01% 386
2018
Q1 		$10K Buy
414
+316
+322% +$8.3K 0.01% 442
2017
Q4 		$3K Buy
+98
New +$2.49K ﹤0.01% 619

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Front Row Advisors's NVO Position: Q3 2024 in Review

Front Row Advisors sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 231 shares — an estimated $33K sold.

Front Row Advisors first reported a position in NVO in Q4 2017 and held it in 24 quarters. The position peaked at $33K in Q2 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Front Row Advisors reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Front Row Advisors sold 231 Novo Nordisk shares in Q3 2024, an estimated $33K.
  • Front Row Advisors first reported a position in Novo Nordisk in Q4 2017 and held it in 24 quarters.
  • Front Row Advisors's Novo Nordisk position peaked at $33K in Q2 2024.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.